The MaMS study: malignancy and multiple sclerosis: incidence and impact of beta-interferon treatment

Project number: 
08-003
Approval date: 
Monday, February 23, 2009
Principal Investigator: 
Kingwell,Elaine
Institution: 
University of British Columbia (UBC)
Funding Agency: 
National Multiple Sclerosis Society,ARSEP Foundation,Canadian Institutes of Health Research(CIHR)
Datasets requested: 
MSP Registration & Premium Billing(BC Ministry of Health)
Medical Services Plan (BC Ministry of Health)
PharmaNet
Consolidation registry (Ministry of Health)
Consolidation - demographic (Ministry of Health)
Hospital Separations (BC Ministry of Health)
consolidation - census geocodes
Deaths (BC Vital Statistics Agency)
Research objective: 

1. To describe the crude and adjusted incidence rate of cancer in the BC MS population.

2. To compare the age- and gender-adjusted incidence of cancer in MS patients with the incidence in the normal risk population.

3. To investigate the effect of treatment with IFN-beta on the incidence of cancer in MS patients

4. To examine life expectancy in the BC MS population

5. To examine risk factors associated with mortality in MS patients and to examine the causes of death, such as cancer, for people with MS.

Publications: 

Journal Publication

  • Kingwell E, Evans C, Zhu F, Oger J, Hashimoto S, Tremlett H (2014) "Assessment of cancer risk with ?-interferon treatment for multiple sclerosis"  J Neuol Nerosurg Psychiatry published online March 4, doi:10.1136/jnnp-2013-307238
  • Kingwell, E.; van der Kop, M.; Zhao, Y.; Shirani, A.; Zhu, F.; Oger, J.; Tremlett, H. (2012) "Relative mortality and survival in multiple sclerosis: Findings from British Columbia, Canada." J. Neurol. Neurosurg Psychiatry 2012:83(1): 61-66
  • Kingwell, E.; Bajdik, C.; Phillips; Zhu, F.; Oger, J.; Hashimoto, S.; Tremlett, H. (2012) "Cancer risk in multiple sclerosis: findings from British Columbia, Canada." Brain 2012; 135:2973-9

Conference abstract/presentation

  • Alotaibi MD, Zhu F, Duggan T, Tremlett H, Kingwell E. Exploring causes associated with MS related deaths on death certificates: a population based study in British Columbia, Canada. Presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Barcelona, Spain October 2015.
  • Kingwell E, Evans C, Zhu F, Duggan T, Oger J, Tremlett H. Cause-specific mortality of multiple sclerosis patients from British Columbia, Canada. presented at The Farr Institute International Conference 2015: Data Intensive Health Research and Care, Edinburgh, Scotland August 2015
  • Alotaibi M, Zhu F, Duggan T, Tremlett H, Kingwell E. When the death certificate says MS: Exploring contributing causes of death. Presented at the Ninth International Scientific Conference for Medical Students in the GCC Countries December 26 – 30, 2014.
  • Kingwell E, Zhu F, Evans C, Duggan T, Oger J, Hashimoto S, Tremlett H. The relative risk of cancer death in men and women with multiple sclerosis: findings from the malignancy in multiple sclerosis (MaMS) study.  Multiple Sclerosis 2013; 19(Suppl.1):108. Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Copenhagen, Denmark October 2013.
  • Kingwell E, Evans C, Zhu F, Hashimoto S, Oger J, Tremlett H. Cancer risk following beta-interferon treatment for multiple sclerosis: Findings from the malignancy in MS (MaMS) Study. Pharmacoepidemiology and Drug Safety 2013;22(Suppl.1):21. Presented at the 29th International Conference on Pharmacoepidemiology & Therapeutics Risk Management; Montreal, QC, August 2013
  • Kingwell E, Evans C, Bajdik C, Hashimoto S, Oger J, Tremlett H. No evidence of increased cancer risk associated with beta-interferon treatment for multiple sclerosis: Preliminary findings from the malignancy in MS (MaMS) Study. Mult. Scler. 2011;17(Suppl.10):S51. Presented at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis; Amsterdam, The Netherlands, October, 2011
  • Kingwell E, Evans C, Duggan T, Zhu F, Oger J, Tremlett H. Causes of death in multiple sclerosis patients from British Columbia, Canada. Multiple Sclerosis 2012; 18 (Suppl.4):310. Presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Lyon, France October 2012
  • Kingwell, E.; Evans, C.; Duggan, T.; Zhu, F.; Oger, J.; Tremlett, H. "Causes of death in multiple sclerosis patients from British Columbia, Canada." Mult Scler 2012;18:310. [Abstract] Poster presentation at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis; Amsterdam, Netherlands; October 2011
  • Kingwell E, Evans C, Duggan T, Zhu F, Oger J, Tremlett H. Causes of death in multiple sclerosis patients from British Columbia, Canada. Multiple Sclerosis 2012; 18 (Suppl.4):310. Presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Lyon, France October 2012
  • Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu, F, Oger J, Tremlett H. Mortality in multiple sclerosis: Findings from British Columbia, Canada. Am. J. Epidemiol. 2011;173:S112. Presented at the 3rd North American Congress of Epidemiology; Montreal, Canada, June 2011
  • Kingwell E, van der Kop M, Zhao Y, Shirani A, Oger J, Tremlett H. Mortality and predictors of survival in multiple sclerosis (MS): Findings from British Columbia, Canada. Presented at the endMS Conference 2010; Whistler, BC, Canada, December 2010.
  • Kingwell E, van der Kop M, Zhao Y, Shirani A, Rieckmann P, Tremlett H. Mortality and predictors of survival in multiple sclerosis (MS): Findings from British Columbia, Canada. Mult. Scler., 2010;16(Suppl. 10):S211  Presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; Gothenburg, Sweden, October 2010

Page last revised: December 5, 2017